Skip to main content
SpringerLink
Log in
Book cover

Die Kosten — Nutzen — Analyse pp 249–300Cite as

A Typology of Cost-Benefit Analyses in the Health Care Sector

  • Chapter

  • 111 Accesses

Part of the book series: Gesundheitssystemforschung ((GESUNDHEITSSYST))

Abstract

Human life is priceless. Our system of values dictates that no expense or effort be spared to prevent or cure a disease or to save a life. Individually and collectively we devote enormous resources to the fight against illness and death. For example, a heart transplant costs approximately U.S. $100 000 (Time, 1984); kidney dialysis costs U.S. $ 28 000 per patient per year (Business Week, 1984). In 1983, health care costs consumed 10.8% of the gross national product of the United States (Business Week, 1984). Today these staggering figures are forcing us to consider the possibility that we may be very close to the point (if we have not already passed it) of spending all we can or should on health. For if life is priceless, so are national security and freedom; if good health is valuable, so are other things, such as human dignity, morality, education, work, and leisure. Yet our resources are finite, and rarely does a program lead to maximal fulfillment of all human desires simultaneously. Invariably, extended pursuit of one human goal compromises the pursuit of others. Thus by design or default, we trade off one need against another, and sometimes a human life against other needs.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   49.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   59.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  • Abel-Smith B (1973) Cost-effectiveness and cost-benefit in cholera control. WHO Chron 27: 407–409

    PubMed  CAS  Google Scholar 

  • Ackoff RL (1962) Scientific method. Wiley, New York

    Google Scholar 

  • Annals of Internal Medicine (1976) (ed) 1976: An agenda for American medicine. Ann Intern Med 85 (6): 818–819

    Google Scholar 

  • Averill RF (1977) A cost-benefit analysis of continued stay certification. Med Care XV (2): 158–173

    Article  Google Scholar 

  • Baker EL, Peterson W, Von Allmen S, Fleming J (1979) Economic impact of a community-wide waterborne outbreak of gastrointestinal illness. Am J Public Health 69 (5): 501–502

    Article  PubMed  Google Scholar 

  • Barlow R (1968) The economic effects of malaria eradication. Research series no 5. Bureau of Public Health Economics, The University of Michigan, Ann Arbor

    Google Scholar 

  • Baumol WJ (1968) On the social rate of discount. Am Econ Rev 58: 788–802

    Google Scholar 

  • Bickley JH, Cavander DC, Maddox JC (1978) Estimating potential and realizable cost savings from Medi-Cal formulary additions: a pilot study of Keflex use in eight diagnosis codes. Eli Lilly

    Google Scholar 

  • Bloom BS, Peterson OL (1973) End results, cost and productivity of coronary care units. Engl J Med 288 (2): 101–102

    Article  Google Scholar 

  • Bootman JL, Rowland C, Wertheimer AI (1979) Cost-benefit analysis: A research tool for evaluating innovative Health programs. Evaluation and the Health Professions 2 (2): 129–154

    Article  CAS  Google Scholar 

  • Boudouris (1975) The economics of methadone programs. Br J Addict 70: 374–380

    Article  CAS  Google Scholar 

  • Brand M, Menzl A, Escher M, Horisberger B (1975) From electroshock therapy to antidepressants: a cost-benefit study. Pharma Information, Basle

    Google Scholar 

  • Braybrook D, Lindblom CE (1963) A strategy for decision. Free Press, New York

    Google Scholar 

  • Brüngger H (1972) Health in cost-benefit analyses: the case of the new drug L-dopa. Schweiz Z Volkswirtschaft Statistik 108: 347–375

    Google Scholar 

  • Bunker JP, Barnes B, Mosteller F (1977) Costs, risks, and benefits of surgery. Oxford University Press, New York

    Google Scholar 

  • Burton GG, Gee GN, Hodgkin JE, Dunham JL (1975) Respiratory care warrants studies for cost-effectiveness. Hospitals 49: 61–71

    PubMed  CAS  Google Scholar 

  • Business Week (1984) The corporate Rx for medical costs. Business Week October 15: 138–148

    Google Scholar 

  • Charnes A, Cooper WW, Kozmetsky G (1973) Measuring, monitoring and modeling quality of life. Management Science 19 (10): 1172–1188

    Article  Google Scholar 

  • Churchman CW (1961) Prediction and optimal decision. Prentice Hall, Englewood Cliffs

    Google Scholar 

  • Churchman CW (1971) On the facility, felicity and morality of measuring social change. Accounting Rev January 46 (1): 30–35

    Google Scholar 

  • Commission on Professional and Hospital Activities (1975) Length of stay in hospitals by diagnosis, United States, North Central Region. CPHA, Ann Arbor, Michigan, p24

    Google Scholar 

  • Cooper BS, Rice DP (1976) The economic cost of illness revisited. Social Security Bull 39 (2): 21–32

    CAS  Google Scholar 

  • Cusano PP, Mayo J, O’Connel RA (1977) The medical economics of lithium treatment for manic depressives. Hosp Community Psychiatry 28 (3): 169–173

    Google Scholar 

  • Dudley HAF (1978) Economics and surgery. J R Soc Med 71: 397–398

    PubMed  CAS  Google Scholar 

  • Dworkin F (1980) On estimating the impact of regulations: a case study on trade secrets disclosure. Managerial and Decision Economics 1 (4): 197–200

    Article  Google Scholar 

  • Fairfax SK (1978) A disaster in environmental movement. Science 199: 743–748

    Article  PubMed  CAS  Google Scholar 

  • Fein R (1977) But, on the other hand: high blood pressure, economics and equity. N Engl J Med 296 (13): 751–753 (editorial)

    Google Scholar 

  • Fineberg VH, Pearlman LA (1981) Benefit and cost analysis of medical interventions: the case of cimetidine and peptic ulcer disease. The implications of cost-effectiveness of medical technology. Office of Technology Assessment, Congress of the United States, Washington DC

    Google Scholar 

  • Fried C (1975) Rights and health care—beyond equity and efficiency. N Engl J Med 293 (5): 241–245

    Article  PubMed  CAS  Google Scholar 

  • Geiser EG, Menz FC (1976) The effectiveness of public dental care programs. Med Care XIV (3): 189–198

    Article  Google Scholar 

  • Gellman DD (1974) Cost-benefit in health care: We need to know much more. Can Med Assoc J 111: 988–989

    PubMed  CAS  Google Scholar 

  • Greenfield S, Komaroff AL, Pass TM, Anderson H, Nessim S (1978) Efficiency and cost of primary care by nurses and physician assistants. N Engl J Med 298: 305–309

    Article  PubMed  CAS  Google Scholar 

  • Gross AM (1976) Is cost-benefit analysis beneficial? Is cost-effectiveness analysis effective? Heller School for Advanced Studies in Social Welfare, Brandeis University. Distributed by National Technical Information Service

    Google Scholar 

  • Gruenfield J (1977) Environmental impact statements: the program that grew and grew. Am Forests 83: 18

    Google Scholar 

  • Hamburg M (1974) Basic statistics. Harcourt, Brace and Jovannovich, New York

    Google Scholar 

  • Hammond KR, Mumpower J, Dennis RL, Fitch S, Crumpacker W (1983) Fundamental obstacles to the use of scientific information in public policy-making. Technological Forecasting Soc Change 24 (4): 287–297

    Article  Google Scholar 

  • Hankin RA (1977) The cost of providing restorative dentistry in an alternative delivery mode. J Public Health Dent 37 (3): 217–223

    Article  PubMed  CAS  Google Scholar 

  • Hannan TH (1976) The benefits and costs of methadone maintenance. Public Policy 24 (2): 197–226

    Google Scholar 

  • Hatry HP (1970) Measuring the effectiveness of nondefense public programs. Operational Res Q October: 772–784

    Google Scholar 

  • Haunalter GV, Chandler VV (1977) Cost of ulcer disease in United States. Stanford Research Institute, Menlo Park

    Google Scholar 

  • Hefner DL (1979) A study to determine the cost-effectiveness of a restrictive formulary: the Louisiana experience. National Pharmaceutical Council, Washington DC

    Google Scholar 

  • Helms RB (1978) Regulating the cost of health care: can we learn from experience? American Enterprise Institute, Washington (Reprint no 85 )

    Google Scholar 

  • Hiatt HH (1975) Protecting the medical commons: who is responsible? N Engl J Med 293 (5): 235–341

    Article  PubMed  CAS  Google Scholar 

  • Hoos IR (1972) Systems analysis in public policy: a critique. University of California Press, Berkeley

    Google Scholar 

  • Illich I (1976) Medical nemesis. Bantam, New York

    Google Scholar 

  • Joglekar P (1979) Cost-benefit studies of therapies: a review of methodologies. La Salle, Philadelphia

    Google Scholar 

  • Joglekar P (1982) Advocacy through convenient definition of societal objectives: the case of cost-benefit analyses in health care. Evaluation Health Prof 5 (4): 363–379

    Article  CAS  Google Scholar 

  • Joglekar P (1984) Cost-benefit studies of health care programs: choosing methods for desired results. Evaluation Health Prof 7 (3): 285–303

    Article  CAS  Google Scholar 

  • Johnson N, Ward E (1972) A new approach to citizen participation: an exploration tying information and utilization. Management Sci 19 (5): 21–34

    Article  Google Scholar 

  • Jondrow JM (1972) A measure of the monetary benefits and costs to consumers of the regulation of prescription drug effectiveness. PhD Dissertation, Univ of Wisconsin

    Google Scholar 

  • Jönsson B (1976) Cost-benefit analysis in public health and medical care. Printlab, Lund, Sweden

    Google Scholar 

  • Keeler EB (1976) The value of a diagnostic test. Rand Corporation (P-5603), Santa Monica

    Google Scholar 

  • Klarman HE (1974) Applications of cost-benefit analysis to the health services and the special case of technologic innovation. Int J Health Serv 4: 325–329

    Article  PubMed  CAS  Google Scholar 

  • Kocher G (1976) Cost benefit analyses in the public system. Pharma Infor. Translated in English by Medical Documents Service, College of Physicians, Philadelphia, Pa

    Google Scholar 

  • Krause BL, Gibbs DR, Brown AH (1977) Is coronary artery surgery so expensive? N Z Med J 86: 570 - 572

    PubMed  CAS  Google Scholar 

  • Kristein MM (1977) Economic issues in prevention. Prev Med 6: 252–264

    Article  PubMed  CAS  Google Scholar 

  • Levin HM (1975) Cost-effectiveness analysis in evaluation research. In: Guttentag H, Struening EL (eds) Handbook of evaluation research, vol II. Sage, Beverly Hills, pp 89–122

    Google Scholar 

  • Luft HS (1976) Benefit-cost analysis and public policy implementation: from normative to positive analysis. Public Policy 24 (4): 437–462

    PubMed  CAS  Google Scholar 

  • Mach EP, Venulet J (1975) The economics of adverse drug reactions. WHO Chron 29: 79–84

    PubMed  CAS  Google Scholar 

  • McBride AD, Boozer JL, Mertz GJ (1976) Rubella vaccination policies. N Engl J Med 294 (20): 1126

    Article  Google Scholar 

  • McGhan WF, Rowland CR, Bootman JL (1978) Cost-benefit and cost-effectiveness: methodologies for evaluating innovative pharmaceutical services. Am J Hosp Pharm 35: 133–140

    PubMed  CAS  Google Scholar 

  • Mechanic D (1978) Approaches to controlling the costs of medical care: short-range and long-range alternatives. N Engl J Med 298 (5): 249–254

    Article  PubMed  CAS  Google Scholar 

  • Mishan EJ (1971) Evaluation of life and limb: a theoretical approach. J Political Econ 79 (4): 687–705

    Article  Google Scholar 

  • Mishan EJ (1976) Cost-benefit analysis. Praeger, New York

    Google Scholar 

  • Mushkin SJ (1962) Health as an investment. J Political Econ 70 (5): 129–159

    Article  Google Scholar 

  • National Center for Health Statistics (1979) The world almanac and book of facts. Newspaper Enterprise Assoc, New York, p956

    Google Scholar 

  • Newspaper Enterprise Association (1978) The world almanac and book of facts 1979. Newspaper Enterprise Association, New York

    Google Scholar 

  • Netherlands Economic Institute (1977) Present cost of peptic ulceration to Dutch economy and possible impact of cimetidine on this cost. NEI, Rotterdam

    Google Scholar 

  • Office of Technology Assessment (OTA) (1980) The implications of cost-effectiveness analysis of medical technology. Congress of the United States, Washington DC

    Google Scholar 

  • Parker WA (1976) Dental therapy assistant: cost-performance analysis. Health Care Studies Division, Academy of Health Science, US Army, Fort Sam Houston, Texas

    Google Scholar 

  • Peltzman S (1974) Regulation of pharmaceutical innovation: the 1962 amendments. American Enterprise Institute, Washington DC

    Google Scholar 

  • Prest AR, Turvey R (1965) Cost-benefit analysis: a survey. Econ J 75: 683–735

    Article  Google Scholar 

  • Quade ES (1975) Analysis for public decisions. Rand Corporation, New York

    Google Scholar 

  • Rice DP, Cooper BS (1967) The economic value of human life. Am J Public Health 57 (11): 1954–1966

    Article  CAS  Google Scholar 

  • Rice D (1969) Measurement and application of illness costs. Public Health Rep 84 (2): 95–101

    Article  PubMed  CAS  Google Scholar 

  • Riddiough M (1979) Cost-effectiveness analysis of vaccination. In: Office of Technology Assessment (ed) Assessing the efficacy and safety of medical techniques. Washington, chap 4, pp 119–161

    Google Scholar 

  • Ridings KW, Isadale IC (1978) The day hospital efficacy and cost-effectiveness. N Z Med J February 22: 129–133

    Google Scholar 

  • Robinson Associates (1978) The impact of cimetidine on the national cost of duodenal ulcers. Bryn Mawr, Pa

    Google Scholar 

  • Rothenberg J (1975) Cost-benefit analysis: a methodological exposition. In: Guttentag M, Struening EL (eds) Handbook of evaluation research. Sage, Beverly Hills

    Google Scholar 

  • Rufener BL, Rachal JV, Cruze AM (1977) Management effectiveness measures for NIDA drug abuse treatment programs. In: National Institute on Drug Abuse (ed) Technical paper, volsl, 2. US Government Printing Office, Washington DC

    Google Scholar 

  • Sassone PG, Schaffer WA (1978) Cost-benefit analysis: a handbook. Academic, London

    Google Scholar 

  • Schindler DW (1976) The impact statement boondoggle. Science 192: 509

    Article  PubMed  CAS  Google Scholar 

  • Schoenbaum SC, Hyde JN, Bartoshesky L, Crampton K (1976 a) Benefit-cost analysis of rubella vaccination policy. N Engl J Med 294 (6): 306–310

    Google Scholar 

  • Schoenbaum SC, McNeil BJ, Kavet J (1976 b) The swine-influenza decision. N Engl J Med 295 (14): 759–785

    Google Scholar 

  • Schramm CJ (1977) Measuring the return on program costs: evaluation of a multiemployer alcoholism treatment program. Am J Public Health 67 (1): 50–51

    Article  PubMed  CAS  Google Scholar 

  • Scitovsky AA, McCall N (1976) Changes in the costs of treatment of selected illnesses 1951-1964-1971. US Dept of HEW publication HRA 77–3161. National Center for Health Services Research, Washington DC

    Google Scholar 

  • Self P (1975) Econocrats and the policy process: the politics and philosophy of cost-benefit analysis. MacMillan, London

    Google Scholar 

  • Simborg DW, Derewicz HJ (1975) A highly automated hospital medication system. Ann Intern Med 83: 342–346

    PubMed  CAS  Google Scholar 

  • Singer E (1973) Social costs of Parkinson’s disease. J Chronic Dis 26: 243–254

    Article  PubMed  CAS  Google Scholar 

  • Singer E (1974) The effect of treatment with levodopa on Parkinson patients’ social functioning and outlook on life. J Chronic Dis 27: 581–594

    Article  PubMed  CAS  Google Scholar 

  • Stange PV, Sumner AT (1978) Predicting treatment costs and life expectancy for end-stage renal disease. N Engl J Med 298 (7): 372–385

    Article  PubMed  CAS  Google Scholar 

  • Stason WB, Weinstein MC (1977) Allocation of resources to manage hypertension. N Engl J Med 296 (13): 732–739

    Article  PubMed  CAS  Google Scholar 

  • Steiner KC, Smith HA (1978) Application of cost-benefit analysis to a PKU screening program. Inquiry X (4): 34–40

    Google Scholar 

  • Steve Thompson Associates (1978) The cost for treatment of ulcer disease — California MEDI-CAL program. Sacramento

    Google Scholar 

  • Stilwell JA (1976) Benefits and costs of schools’ BCG vaccination programme. Br Med J 1: 1002–1004

    Article  PubMed  CAS  Google Scholar 

  • Terleckyj NE (1973) National goals accounting. National Planning Association, Washington DC

    Google Scholar 

  • Time ( 1984 ) One miracle, many doubts. Time DeclO: 70–77

    Google Scholar 

  • Velez-Gil A, Wilson D, Pelaez RN (1976) A simplified system for surgical operations: the economics of treating hernia. Surgery 77 (3): 391–394

    Google Scholar 

  • Vollman TE (1973) Operations management. Addison Wesley, Reading

    Google Scholar 

  • Weinstein MC, Stason WB (1977) Foundations of cost-effectiveness analysis for health and medical practices. N Engl J Med 296 (13): 716–721

    Article  PubMed  CAS  Google Scholar 

  • Weisbrod BA (1971) Costs and benefits of medical research: a case study of poliomyelitis. J Political Econ 79 (3): 527–544 Weisbrod BA, Test MA, Stein LT ( 1978 ) An alternative to mental hospital treatment. III. Economic benefit-cost analysis (unpublished)

    Google Scholar 

  • Weisbrod BA, Test MA, Stein LT (1978) An alternative to mental hospital treatment. III. Economic benefit-cost analysis (unpublished)

    Google Scholar 

  • Williams A (1974) The cost-benefit approach. Br Med Bull 3: 252–256

    Google Scholar 

  • Williamson JW, Goldschmidt PG, Jillson IA (1979) Bipolar disorder: a state of the science report. Policy Research, Baltimore

    Google Scholar 

  • Zeckhauser R (1975) Procedures for valuing lives. Public Policy 23 (4): 419–464

    PubMed  CAS  Google Scholar 

References

  • Barlow R (1968) The economic effects of malaria eradication. Research series 5. Bureau of Public Health Economics. University of Michigan, Ann Arbor

    Google Scholar 

  • Baumol WJ (1968) On the social rate of discount. Am Econ Rev 58,4: 788–802

    Google Scholar 

  • Bickley JH, Cavander DC, Maddox JC (1978) Estimating potential and realizable cost savings from Medi-Cal formulary additions: a pilot study of Keflex use in eight diagnosis codes. Lilly

    Google Scholar 

  • Boden LI (1979) Cost-benefit analysis: caveat emptor. Am J Public Health 69,12: 1210–1211

    Google Scholar 

  • Bootman JL, Rowland C, Wertheimer AI (1979) Cost-benefit analysis: a research tool for evaluating innovative health programs. Evaluation and the Health Professions 2 (2): 129–154

    Article  CAS  Google Scholar 

  • Brand M, Menzl A, Escher M, Horisberger B (1975) From electroshock therapy to antidepressants: a cost-benefit study. Pharma Information, Basle

    Google Scholar 

  • Brüngger H (1972) Health in cost-benefit analyses: the case of the new drug L-dopa. Schweiz Zeitschr Volkswirt Stat 347–375

    Google Scholar 

  • Bunker JP, Barnes B, Mosteller F (1977) Costs, risks, and benefits of surgery. Oxford University Press, New York

    Google Scholar 

  • Card WJ, Mooney GH (1977) What is the monetary value of human life? Br Med J 2: 1627–1629

    Article  PubMed  CAS  Google Scholar 

  • Churchman C (1971) On the facility, felicity and morality of measuring social change. Account Rev 46: 30–35

    Google Scholar 

  • Conley RW (1975) Issues in benefit-cost analysis of the vocational rehabilitation program. Am Rehabil (November/December): 19 - 24

    Google Scholar 

  • Cooper BS, Rice DP (1976) The economic cost of illness revisited. Soc Secur Bull 39,2: 21–32

    Google Scholar 

  • Cusano PP, Mayo J, O’Connel RA (1977) The medical economics of lithium treatment for manic depressives. Hosp Community Psychiatry 28, 3: 169–173

    Google Scholar 

  • Drummond MF (1978) Evaluation and the National Health Service. In: Culyer AJ, Wright KG (eds) Economic aspects of health services. Robertson, London

    Google Scholar 

  • Dworkin F (1980) On estimating the economic impact of regulations: a case study on trade secrets disclosure. Managerial Decision Econ 1,4: 197–200

    Google Scholar 

  • Fein R (1977) But, on the other hand: high blood pressure, economics and equity. N Engl J Med 296,13: 751–753

    Google Scholar 

  • Fineberg VH, Pearlman LA (1981) Benefit and cost analysis of medical intervention: the case of ci- metidine and peptic ulcer disease. The implications of cost-effectiveness of medical technology. Office of Technology Assessment, Congress of the United States, Washington DC

    Google Scholar 

  • Fried C (1975) Rights and health care - beyond equity and efficiency. N Engl J Med 293, 5: 241–245

    Article  PubMed  CAS  Google Scholar 

  • Geiser EG, Menz FC (1976) The effectiveness of public dental care programs. Med Care XIV, e: 189 - 198

    Google Scholar 

  • Gross AM (1976) Is cost-benefit analysis beneficial? Is cost-effectiveness analysis effective? Heller School for Advanced Studies in Social Welfare. Brandis University National Technical Information Service and US Department of Commerce, Waltham

    Google Scholar 

  • Hannan TH (1976) The benefits and costs of methadone maintenance. Public Policy 24, 2:197–226

    Google Scholar 

  • Hatry HP ( 1970 ) Measuring the effectiveness of nondefense public programs. Operational Res Q (October): 772–784

    Google Scholar 

  • Haunalter GV, Chandler W (1977) Cost of ulcer disease in the United States. Stanford Research Institute, Menlo Park

    Google Scholar 

  • Hefner DL (1979) A study to determine the cost-effectiveness of a restrictive formulary: the Louisiana experience. National Pharmaceutical Council, Washington DC

    Google Scholar 

  • Hoos IR (1972) Systems analysis in public policy: a critique. University of California Press, Los Angeles

    Google Scholar 

  • Joglekar PN (1979) Cost-benefits of health care programs: a review of methodologies used. Presented at national conference of the Operations Research Society of America, New Orleans

    Google Scholar 

  • Joglekar PN (1982) Advocacy through convenient definition of societal objectives: the case of cost-benefit analysis in health care. Evaluation Health Professions 5: 363–379

    Article  CAS  Google Scholar 

  • Jónsson B (1976) Cost-benefit analysis in public health and medical care. Printlab, Lund

    Google Scholar 

  • Levine HM (1975) Cost-effectiveness analysis in evaluation research. In: Gettentag M, Struening EL (eds) Handbook of evaluation research, vol II. Sage, Beverly Hills, pp 89–112

    Google Scholar 

  • McBride AD, Boozer JL, Mertz GJ (1976) Rubella vaccination policies. N Engl J Med 294: 1126

    Article  Google Scholar 

  • Mishan EJ (1971) Evaluation of life and limb: a theoretical approach. J Polit Econ 79, 4: 687–705

    Article  Google Scholar 

  • Mushkin SJ (1962) Health as an investment. J Polit Econ 70, 5: 129–159

    Article  Google Scholar 

  • Netherlands Economic Institute (1977) Present cost of peptic ulceration to Dutch economy and possible impact of cimetidine on this cost. Rotterdam

    Google Scholar 

  • Peltzman S (1974) Regulation of pharmaceutical innovation: the 1962 amendments. American Enterprise Institute for Public Policy Research, Washington DC

    Google Scholar 

  • Quade ES (1975) Analysis for public decisions. Elsevier, New York

    Google Scholar 

  • Riddiough M (1979) Cost-effectiveness analysis of vaccination. Office of technology assessment report 4. Washington DC

    Google Scholar 

  • Robinson Associates (1978) The impact of cimetidine on the national cost of duodenal ulcers. Bryn Mawr

    Google Scholar 

  • Rothenberg J (1975) Cost-benefit analysis: a methodological exposition. In: Gettentag M, Struening EL (eds) Handbook of evaluation research. Sage, Beverly Hills: 55–88

    Google Scholar 

  • Rufener BL, Rachal VJ, Cruze AM (1977) Management effectiveness measure for NIDA drug abuse treatment programs, vol I, I I. National Institute on Drug Abuse. Government Printing Office, Washington DC

    Google Scholar 

  • Sassone PG, Schaffer WA (1978) Cost-benefit analysis—a handbook. Academic, New York

    Google Scholar 

  • Schoenbaum SC, Hyde JN Jr, Bartodhesky L, Crampton K (1976) Benefit-cost analysis of rubella vaccination policy. N Engl J Med 294: 306–310

    Article  PubMed  CAS  Google Scholar 

  • Schramm CJ (1977) Measuring the return on program costs: evaluation of a multi-employer alcoholism treatment program. Am J Public Health 67,1: 50–51

    Google Scholar 

  • Self P (1975) Econocrats and the policy process: the politics and philosophy of cost-benefit analysis. Macmillan, London

    Google Scholar 

  • Stason WB, Weinstein MC (1977) Allocation of resources to manage hypertension. N Engl J Med 296: 732–739

    Article  PubMed  CAS  Google Scholar 

  • Steiner KC, Smith HA (1976) Application of cost-benefit analysis to a PKU screening program. Inquiry X, 4: 34–40

    Google Scholar 

  • Stilwell JA (1976) Benefits and costs to schools’ BCG vaccination programs. Br Med J1: 1002–1004

    Article  CAS  Google Scholar 

  • Weinstein MC, Stason WB (1977) Foundations of cost-effectiveness analysis for health and medical practices. N Engl J Med 296: 716–721

    Article  PubMed  CAS  Google Scholar 

  • Weisbrod BA (1971) Costs and benefits of medical research: a case study of poliomyelitis. J Polit Econ 79,3: 527–544

    Google Scholar 

References

  • Barlow R (1968) The economic effects of malaria eradication. Research series 5. Bureau of public health economics. University of Michigan, Ann Arbor

    Google Scholar 

  • Joglekar P (1979) Cost-benefits of health programs: a review of methodologies. TIMS/ORSA, New Orleans

    Google Scholar 

  • Joglekar P (1980) Cost-benefit studies of health care programs: choosing methods for desired results. TIMS/ORSA, Washington DC

    Google Scholar 

  • Riddiough M (1979) Cost-effectiveness analysis of vaccination. Office of Technology Assessment, Washington DC

    Google Scholar 

  • Weinstein MC, Stason WB (1977) Foundations of cost-effectiveness analysis for health and medical practices. N Engl J Med 296: 716–721

    Article  PubMed  CAS  Google Scholar 

Download references

Authors
  1. P. Joglekar
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. M. L. Paterson
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Interdisziplinäres Forschungszentrum für die Gesundheit St. Gallen, Rorschacher Straße 103 c, CH-9007, St. Gallen, Schweiz

    Bruno Horisberger

  2. GSF-Gesellschaft für Strahlen- und Umweltforschung mbH, München, Germany

    Wilhelm van Eimeren

  3. Informatik und Systemforschung, MEDIS-Institut für Medizinische, Ingolstädter Landstraße 1, D-8042, Oberschleißheim, Germany

    Wilhelm van Eimeren

Rights and permissions

Reprints and permissions

Copyright information

© 1986 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Joglekar, P., Paterson, M.L. (1986). A Typology of Cost-Benefit Analyses in the Health Care Sector. In: Horisberger, B., van Eimeren, W. (eds) Die Kosten — Nutzen — Analyse. Gesundheitssystemforschung. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-70521-2_5

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-70521-2_5

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-540-15471-6

  • Online ISBN: 978-3-642-70521-2

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation